Form 8-K - Current report:
SEC Accession No. 0001725160-21-000219
Filing Date
2021-11-10
Accepted
2021-11-10 07:48:02
Documents
13
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20211110.htm   iXBRL 8-K 42583
2 EX-99.1 zntl_q32021earningspressre.htm EX-99.1 71513
  Complete submission text file 0001725160-21-000219.txt   268932

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20211110.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20211110_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20211110_pre.xml EX-101.PRE 13581
6 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20211110_htm.xml XML 11772
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 211394454
SIC: 2834 Pharmaceutical Preparations